However, among blood immune subsets, MIF mRNA was predominantly expressed by B cells compared to paired T cells, monocytes and dendritic cells (Fig. 4C), but downregulated in B cells from RRMS patients versus HC (p < 0.01) and even further in B cells of CIS patients (CIS vs. HC, p < 0.0001; CIS vs. RRMS, p < 0.01; Fig. 4D). Here, MIF is linked to in situ carcinoma.